Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 317

1.

Pharmacodynamics of Ceftazidime plus Avibactam against KPC-2 Bearing Isolates of Klebsiella pneumoniae in a Hollow Fiber Infection Model.

Drusano GL, Shields RK, Mtchedlidze N, Nguyen MH, Clancy CJ, Vicciarelli M, Louie A.

Antimicrob Agents Chemother. 2019 Jun 3. pii: AAC.00462-19. doi: 10.1128/AAC.00462-19. [Epub ahead of print]

PMID:
31160285
2.

Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa.

Papp-Wallace KM, Zeiser ET, Becka SA, Park S, Wilson BM, Winkler ML, D'Souza R, Singh I, Sutton G, Fouts DE, Chen L, Kreiswirth BN, Ellis-Grosse EJ, Drusano GL, Perlin DS, Bonomo RA.

J Infect Dis. 2019 May 17. pii: jiz149. doi: 10.1093/infdis/jiz149. [Epub ahead of print]

PMID:
31099835
3.

Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β-Lactam plus Aminoglycoside in Gram-negatives: A Meta-analysis of Randomized, Controlled Trials.

Jiao Y, Moya B, Chen MJ, Zavascki AP, Tsai H, Tao X, Sutaria DS, Louie A, Boyce JD, Lucas DD, Kim TH, Tsuji BT, Bonomo RA, Drusano GL, Bulitta JB.

Antimicrob Agents Chemother. 2019 Apr 15. pii: AAC.00425-19. doi: 10.1128/AAC.00425-19. [Epub ahead of print]

PMID:
30988147
4.

Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans.

Bulitta JB, Hope WW, Eakin AE, Guina T, Tam VH, Louie A, Drusano GL, Hoover JL.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02307-18. doi: 10.1128/AAC.02307-18. Print 2019 May. Review.

5.

Breakpoint determination when multiple organisms are tested for effect targets.

Drusano GL, Louie A.

Eur J Pharm Sci. 2019 Mar 15;130:196-199. doi: 10.1016/j.ejps.2019.01.033. Epub 2019 Jan 31.

PMID:
30711687
6.

Effect of Moxifloxacin plus Pretomanid against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an In Vitro Assay.

de Miranda Silva C, Hajihosseini A, Myrick J, Nole J, Louie A, Schmidt S, Drusano GL.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01695-18. doi: 10.1128/AAC.01695-18. Print 2019 Jan.

7.

Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation.

Heinrichs MT, Drusano GL, Brown DL, Maynard MS, Sy SKB, Rand KH, Peloquin CA, Louie A, Derendorf H.

Int J Antimicrob Agents. 2019 Mar;53(3):275-283. doi: 10.1016/j.ijantimicag.2018.10.012. Epub 2018 Oct 29.

PMID:
30385322
8.

The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model.

Drusano GL, Neely MN, Yamada WM, Duncanson B, Brown D, Maynard M, Vicchiarelli M, Louie A.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01682-18. doi: 10.1128/AAC.01682-18. Print 2018 Dec.

9.

Activity of Moxifloxacin against Mycobacterium tuberculosis in Acid Phase and Nonreplicative-Persister Phenotype Phase in a Hollow-Fiber Infection Model.

Louie A, Duncanson B, Myrick J, Maynard M, Nole J, Brown D, Schmidt S, Neely M, Scanga CA, Peloquin C, Drusano GL.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01470-18. doi: 10.1128/AAC.01470-18. Print 2018 Dec.

10.

Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis.

Bulitta JB, Jiao Y, Drescher SK, Oliver A, Louie A, Moya B, Tao X, Wittau M, Tsuji BT, Zavascki AP, Shin BS, Drusano GL, Sörgel F, Landersdorfer CB.

Clin Pharmacokinet. 2019 Feb;58(2):143-156. doi: 10.1007/s40262-018-0678-x. Review.

PMID:
29936678
11.

Antiviral Effects of Clinically-Relevant Interferon-α and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM).

Pires de Mello CP, Drusano GL, Rodriquez JL, Kaushik A, Brown AN.

Viruses. 2018 Jun 9;10(6). pii: E317. doi: 10.3390/v10060317.

12.

Effect of Linezolid plus Bedaquiline against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an In Vitro Assay.

de Miranda Silva C, Hajihosseini A, Myrick J, Nole J, Louie A, Schmidt S, Drusano GL.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00856-18. doi: 10.1128/AAC.00856-18. Print 2018 Aug.

13.

Linezolid Kills Acid-Phase and Nonreplicative-Persister-Phase Mycobacterium tuberculosis in a Hollow-Fiber Infection Model.

Drusano GL, Myrick J, Maynard M, Nole J, Duncanson B, Brown D, Schmidt S, Neely M, Scanga CA, Peloquin C, Louie A.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00221-18. doi: 10.1128/AAC.00221-18. Print 2018 Aug.

14.

First Penicillin-Binding Protein Occupancy Patterns of β-Lactams and β-Lactamase Inhibitors in Klebsiella pneumoniae.

Sutaria DS, Moya B, Green KB, Kim TH, Tao X, Jiao Y, Louie A, Drusano GL, Bulitta JB.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e00282-18. doi: 10.1128/AAC.00282-18. Print 2018 Jun.

15.

Erratum for Drusano et al., "Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia".

Drusano GL, Corrado ML, Girardi G, Ellis-Grosse EJ, Wunderink RG, Donnelly H, Leeper KV, Brown M, Malek T, Hite RD, Ferrari M, Djureinovic D, Kollef MH, Mayfield L, Doyle A, Chastre J, Combes A, Walsh TJ, Dorizas K, Alnuaimat H, Morgan BE, Rello J, Mazo CA, Jones RN, Flamm RK, Woosley L, Ambrose PG, Bhavnani S, Rubino CM, Bulik CC, Louie A, Vicchiarelli M, Berman C.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e00198-18. doi: 10.1128/AAC.00198-18. Print 2018 Apr. No abstract available.

16.

Determination of the Dynamically Linked Indices of Fosfomycin for Pseudomonas aeruginosa in the Hollow Fiber Infection Model.

Louie A, Maynard M, Duncanson B, Nole J, Vicchiarelli M, Drusano GL.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e02627-17. doi: 10.1128/AAC.02627-17. Print 2018 Jun.

17.

Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV).

Brown AN, Liu L, Rodriquez JL, Zhao L, Schuster L, Li E, Wang GP, Neely MN, Yamada W, Drusano GL.

Sci Rep. 2017 Oct 31;7(1):14421. doi: 10.1038/s41598-017-15007-2.

18.

Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system.

Pires de Mello CP, Drusano GL, Adams JR, Shudt M, Kulawy R, Brown AN.

Eur J Pharm Sci. 2018 Jan 1;111:443-449. doi: 10.1016/j.ejps.2017.10.027. Epub 2017 Oct 25.

19.

Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia.

Drusano GL, Corrado ML, Girardi G, Ellis-Grosse EJ, Wunderink RG, Donnelly H, Leeper KV, Brown M, Malek T, Hite RD, Ferrari M, Djureinovic D, Kollef MH, Mayfield L, Doyle A, Chastre J, Combes A, Walsh TJ, Dorizas K, Alnuaimat H, Morgan BE, Rello J, Mazo CA, Jones RN, Flamm RK, Woosley L, Ambrose PG, Bhavnani S, Rubino CM, Bulik CC, Louie A, Vicchiarelli M, Berman C.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01323-17. doi: 10.1128/AAC.01323-17. Print 2018 Jan. Erratum in: Antimicrob Agents Chemother. 2018 Mar 27;62(4):.

20.

Pre-clinical in vitro infection models.

Drusano GL.

Curr Opin Pharmacol. 2017 Oct;36:100-106. doi: 10.1016/j.coph.2017.09.011. Epub 2017 Oct 14. Review.

PMID:
29035729
21.

Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system.

Pomeroy JJ, Drusano GL, Rodriquez JL, Brown AN.

Antiviral Res. 2017 Oct;146:149-152. doi: 10.1016/j.antiviral.2017.09.001. Epub 2017 Sep 4.

22.

Evaluation of Combination Drug Therapy for Treatment of Antibiotic-Resistant Inhalation Anthrax in a Murine Model.

Heine HS, Shadomy SV, Boyer AE, Chuvala L, Riggins R, Kesterson A, Myrick J, Craig J, Candela MG, Barr JR, Hendricks K, Bower WA, Walke H, Drusano GL.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00788-17. doi: 10.1128/AAC.00788-17. Print 2017 Sep.

23.

Stepping Off the Resistance Treadmill.

Drusano GL.

J Infect Dis. 2017 Jul 15;216(2):150-152. doi: 10.1093/infdis/jix212. No abstract available.

PMID:
28475769
24.

Reply to Scagnolari et al.

Brown AN, Gallegos KM, D'Argenio DZ, Drusano GL.

J Infect Dis. 2017 Feb 1;215(3):493-494. doi: 10.1093/infdis/jiw580. No abstract available.

PMID:
28003357
25.

From lead optimization to NDA approval for a new antimicrobial: Use of pre-clinical effect models and pharmacokinetic/pharmacodynamic mathematical modeling.

Drusano GL.

Bioorg Med Chem. 2016 Dec 15;24(24):6401-6408. doi: 10.1016/j.bmc.2016.08.034. Epub 2016 Aug 27. Review.

PMID:
27612961
26.

Chikungunya Virus: In Vitro Response to Combination Therapy With Ribavirin and Interferon Alfa 2a.

Gallegos KM, Drusano GL, D Argenio DZ, Brown AN.

J Infect Dis. 2016 Oct 15;214(8):1192-7. doi: 10.1093/infdis/jiw358. Epub 2016 Aug 5.

27.

Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality.

Hope W, Drusano GL, Rex JH.

J Antimicrob Chemother. 2016 Nov;71(11):3008-3019. Epub 2016 Aug 5. Review.

PMID:
27494925
28.

Natural History of Francisella tularensis in Aerosol-Challenged BALB/c Mice.

Heine HS, Chuvala L, Riggins R, Cirz R, Cass R, Louie A, Drusano GL.

Antimicrob Agents Chemother. 2016 Jan 11;60(3):1834-40. doi: 10.1128/AAC.02887-15.

29.

Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2.

Drusano GL, Hope W, MacGowan A, Louie A.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1194-201. doi: 10.1128/AAC.02231-15. Review.

30.

Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1.

Drusano GL, Louie A, MacGowan A, Hope W.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1183-93. doi: 10.1128/AAC.02177-15. Review.

31.

Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.

Bhavnani SM, Ambrose PG, Hammel JP, Rubino CM, Drusano GL.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1600-7. doi: 10.1128/AAC.02967-15.

32.

Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.

Brown AN, Drusano GL, Adams JR, Rodriquez JL, Jambunathan K, Baluya DL, Brown DL, Kwara A, Mirsalis JC, Hafner R, Louie A.

MBio. 2015 Nov 3;6(6):e01741-15. doi: 10.1128/mBio.01741-15.

33.

Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.

Docobo-Pérez F, Drusano GL, Johnson A, Goodwin J, Whalley S, Ramos-Martín V, Ballestero-Tellez M, Rodriguez-Martinez JM, Conejo MC, van Guilder M, Rodríguez-Baño J, Pascual A, Hope WW.

Antimicrob Agents Chemother. 2015 Sep;59(9):5602-10. doi: 10.1128/AAC.00752-15. Epub 2015 Jun 29.

34.

In memoriam: William A. Craig.

Theuretzbacher U, Ambrose PG, MacGowan AP, Andes DR, Sörgel F, Derendorf H, Mouton JW, Drusano GL, Tulkens PM, Dudley MN, Cars O, Nation RL.

Antimicrob Agents Chemother. 2015;59(6):2971. doi: 10.1128/AAC.00849-15. Epub 2015 Apr 20. No abstract available.

35.

Pharmacokinetic determinants of virological response to raltegravir in the in vitro pharmacodynamic hollow-fiber infection model system.

Brown AN, Adams JR, Baluya DL, Drusano GL.

Antimicrob Agents Chemother. 2015 Jul;59(7):3771-7. doi: 10.1128/AAC.00469-15. Epub 2015 Apr 13.

36.

Pharmacodynamic evaluation of the activities of six parenteral vancomycin products available in the United States.

Louie A, Boyne MT 2nd, Patel V, Huntley C, Liu W, Fikes S, Kurhanewicz S, Rodriquez J, Robbins N, Brown D, Baluya D, Drusano GL.

Antimicrob Agents Chemother. 2015 Jan;59(1):622-32. doi: 10.1128/AAC.03710-14. Epub 2014 Nov 10.

37.

Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections.

Bhavnani SM, Hammel JP, Van Wart SA, Rubino CM, Reynolds DK, Forrest A, Drusano GL, Khariton T, Friedland HD, Riccobene TA, Ambrose PG.

Antimicrob Agents Chemother. 2015 Jan;59(1):372-80. doi: 10.1128/AAC.02531-14. Epub 2014 Nov 3.

38.

Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia.

Louie A, Liu W, VanGuilder M, Neely MN, Schumitzky A, Jelliffe R, Fikes S, Kurhanewicz S, Robbins N, Brown D, Baluya D, Drusano GL.

J Infect Dis. 2015 Apr 15;211(8):1326-33. doi: 10.1093/infdis/jiu603. Epub 2014 Oct 31.

39.

Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis.

Drusano GL, Neely M, Van Guilder M, Schumitzky A, Brown D, Fikes S, Peloquin C, Louie A.

PLoS One. 2014 Jul 8;9(7):e101311. doi: 10.1371/journal.pone.0101311. eCollection 2014.

40.

Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?

Lodise TP, Drusano GL, Zasowski E, Dihmess A, Lazariu V, Cosler L, McNutt LA.

Clin Infect Dis. 2014 Sep 1;59(5):666-75. doi: 10.1093/cid/ciu398. Epub 2014 May 27.

PMID:
24867791
41.

Quantifying the matrix of relationships between reduced vancomycin susceptibility phenotypes and outcomes among patients with MRSA bloodstream infections treated with vancomycin .

Lodise TP, Drusano GL, Lazariu V, El-Fawal N, Evans A, Graffunder E, Stellrecht K, Mendes RE, Jones RN, Cosler L, McNutt LA.

J Antimicrob Chemother. 2014 Sep;69(9):2547-55. doi: 10.1093/jac/dku135. Epub 2014 May 19.

PMID:
24840624
42.

Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model.

Drusano GL, Liu W, Fikes S, Cirz R, Robbins N, Kurhanewicz S, Rodriquez J, Brown D, Baluya D, Louie A.

J Infect Dis. 2014 Oct 15;210(8):1319-24. doi: 10.1093/infdis/jiu237. Epub 2014 Apr 22.

43.

Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.

Heine HS, Louie A, Adamovicz JJ, Amemiya K, Fast RL, Miller L, Opal SM, Palardy J, Parejo NA, Sörgel F, Kinzig-Schippers M, Drusano GL.

Antimicrob Agents Chemother. 2014 Jun;58(6):3276-84. doi: 10.1128/AAC.02420-14. Epub 2014 Mar 31.

44.

Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate.

Lodise TP, Drusano GL.

Clin Infect Dis. 2014 Jan;58 Suppl 1:S28-34. doi: 10.1093/cid/cit615. Review.

PMID:
24343829
45.

In memoriam: John P. Quinn, MD.

Perez F, Arias CA, Bush K, Drusano GL, Lolans K, Munoz-Price LS, Nicolau DP, Queenan AM, Rice LB, Segreti J, Shlaes DM, Weinstein RA, Bonomo RA.

Clin Infect Dis. 2014 Mar;58(5):748-50. doi: 10.1093/cid/cit801. Epub 2013 Dec 12. No abstract available.

46.

Are vancomycin trough concentrations adequate for optimal dosing?

Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, Lodise TP.

Antimicrob Agents Chemother. 2014;58(1):309-16. doi: 10.1128/AAC.01653-13. Epub 2013 Oct 28.

47.

Hollow-fiber pharmacodynamic studies and mathematical modeling to predict the efficacy of amoxicillin for anthrax postexposure prophylaxis in pregnant women and children.

Louie A, Vanscoy B, Liu W, Kulawy R, Drusano GL.

Antimicrob Agents Chemother. 2013 Dec;57(12):5946-60. doi: 10.1128/AAC.02616-12. Epub 2013 Sep 16.

48.

Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia.

Louie A, Liu W, Fikes S, Brown D, Drusano GL.

Antimicrob Agents Chemother. 2013 Jun;57(6):2788-92. doi: 10.1128/AAC.02624-12. Epub 2013 Apr 9.

49.

Natural history of Yersinia pestis pneumonia in aerosol-challenged BALB/c mice.

Heine HS, Chuvala L, Riggins R, Hurteau G, Cirz R, Cass R, Louie A, Drusano GL.

Antimicrob Agents Chemother. 2013 May;57(5):2010-5. doi: 10.1128/AAC.02504-12. Epub 2013 Feb 12.

50.

Saving lives with optimal antimicrobial chemotherapy.

Drusano GL, Lodise TP.

Clin Infect Dis. 2013 Jan;56(2):245-7. doi: 10.1093/cid/cis863. Epub 2012 Oct 16. No abstract available.

PMID:
23074312

Supplemental Content

Loading ...
Support Center